VivoSeq
Oncology

Large B-Cell Lymphoma

13

Pipeline Programs↗

6

Active Trials↗

10

Companies Involved↗

Large B-cell Lymphoma is an emerging landscape with 13 programs across 10 companies. The most active players are Hikma Pharmaceuticals LLC, Hebei Senlang Biotechnology Inc., Ltd., Sanofi. 7 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

42/100

Pipeline Velocity

15/100

Mech. Concentration

20/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

H

Hikma Pharmaceuticals LLC

1 program

Phase 1H

Hebei Senlang Biotechnology Inc., Ltd.

1 program

Phase 1Sanofi logo

Sanofi

1 program

Phase 2B

Beijing Biotech

1 program

Phase 2Eli Lilly logo

Eli Lilly

2 programs

Phase 3Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

77%

Small molecule

10 of 13 classified programs — the dominant modality here.

23%ALL OTHERSMonoclonal antibody18%Antibody–drug conjugate18%Cell therapy18%

Small molecule leads; the ring shows all 13 classified programs, each share of the total. Modality classified for 93% of 14 pipeline programs.

Analysis

Trial Status

6

clinical trials

Recruiting4 · 67%
Active, not recruiting1 · 17%
Not yet recruiting1 · 17%

Clinical Trials

Trial Activity

6 trials

A Pilot Trial of Bridging Radiation Therapy With Oral Vancomycin for Patients With B-cell Lymphomas Undergoing CAR-T Therapy
Recruiting·AAbramson Cancer Center at Penn Medicine·Phase 1·NCT07478848·14 enrolled
Phase 2 Trial of Lisocabtagene Maraleucel for Minimal Residual Disease in Patients With Large B-cell Lymphoma
Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT07316010·50 enrolled
A Randomized, Open-label Study Evaluating the Efficacy and Safety of Cemacabtagene Ansegedleucel in Participants With Minimal Residual Disease After Response to First Line Therapy for Large B-cell Lymphoma
Recruiting·AAllogene Therapeutics·Phase 2·NCT06500273·250 enrolled
A Randomized, Open-label, Phase 3 Study of Acalabrutinib in Combination With Rituximab and Reduced Dose CHOP (R-miniCHOP) in OldEr Adults With Untreated Diffuse Large B-Cell Lymphoma
Recruiting·UUniversität des Saarlandes·Phase 3·NCT05820841·330 enrolled
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants With Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1)
Active, not recruiting·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 3·NCT06356129·850 enrolled
A Single-Arm, Prospective Study of Pola-R-CHP Plus Sonrotoclax in Patients With Previously Untreated Large B-Cell Lymphoma (LBCL) With High BCL2 Expression / Double-Hit Lymphoma
Not yet recruiting·RRuijin Hospital·Preclinical·NCT07638787·40 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)